Neil Kumar, BridgeBio CEO (J.T. MacMillan Photography for Endpoints News)

Bridge­Bio touts ad­di­tion­al AT­TR-CM drug da­ta in new analy­ses of Phase 3 tri­al

Bridge­Bio re­leased ad­di­tion­al analy­ses of its Phase 3 study of aco­ramidis in AT­TR-CM on Wednes­day, spot­light­ing the link be­tween serum transthyretin (TTR) lev­els and the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.